RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is December 30, 2020. The rights plan expires, without any further action being required to be taken by ADMA's Board of Directors, on December 15, 2021. The adoption of the rights plan is intended to protect ADMA and its stockholders from the actions of third parties that ADMA's Board of Directors determines are not in the best interests of ADMA and its stockholders, and to enable all stockholders to realize the full potential value of their investment in ADMA.